{"url_path":"/sec/irwd/8-k/2026-05-21/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K/A","doc_date":"2026-05-21","source_url":"https://www.sec.gov/Archives/edgar/data/1446847/0001104659-26-065140-index.html","accession_number":"0001104659-26-065140","cik":"0001446847","ticker":"IRWD","issuer_name":"IRONWOOD PHARMACEUTICALS INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1446847/0001104659-26-065140-index.html","primary_entity_key":"0001446847","primary_entity_name":"IRONWOOD PHARMACEUTICALS INC"},"word_count":464,"has_tables":true,"body_markdown":"false\n0001446847\n\n0001446847\n\n2026-05-08\n2026-05-08\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\n \n\n \n\n \n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**Washington, D.C. 20549**\n\n \n\n**FORM 8-K/A**\n\n \n\n**Amendment No.\n1**\n\n \n\n**Current Report Pursuant to**\n\n**Section 13 or 15(d) of the**\n\n**Securities Exchange Act of 1934**\n\n \n\nDate of Report (Date of\nEarliest Event Reported):\n\nMay 8, 2026\n\n \n\n**IRONWOOD\nPHARMACEUTICALS, INC.**\n\n*(Exact name of registrant as specified in its\ncharter)*\n\n \n\n**Delaware**\n \n**001-34620**\n \n**04-3404176**\n\n*(State\nor other jurisdiction*\n \n*(Commission File Number)* \n*(I.R.S.\nEmployer*\n\n*of\nincorporation)*\n \n  \n*Identification\nNumber)*\n\n \n\n**100\nSummer Street****, Suite\n2300**\n \n \n \n \n\n**Boston****,\nMassachusetts**\n \n \n \n**02110**\n\n*(Address\nof principal*\n \n \n \n* (Zip code)*\n\n*executive\noffices)*\n \n \n \n \n\n \n\n**(617****)\n621-7722**\n\n*(Registrant’s telephone number,*\n\n*including area code)*\n\n \n\nCheck the appropriate box below if the Form 8-K\nfiling is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):\n\n \n\n¨Written\ncommunications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n \n\n¨Soliciting\nmaterial pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\n \n\n¨Pre-commencement\ncommunications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\n \n\n¨Pre-commencement\ncommunications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))\n\n \n\nSecurities registered pursuant to Section 12(b) of the Act: \n\n \n\nTitle of each class\nTrading Symbol(s)\nName of each exchange on which\n\nregistered\n\nClass\nA common stock, $0.001 par value\nIRWD\nNasdaq\nGlobal Select Market\n\n \n\nIndicate by check mark whether the registrant is\nan emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of\nthe Securities Exchange Act of 1934 (§240.12b-2 of this chapter).\n\n \n\nEmerging\ngrowth company ¨\n\n \n\nIf\nan emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying\nwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨\n\n \n\n \n\n \n\n \n\n**Explanatory Note**\n\n** **\n\nThis Current Report on Form 8-K/A is being filed\nas an amendment (this “Amendment No. 1”) to the Current Report on Form 8-K filed by Ironwood Pharmaceuticals, Inc. (the “Company”)\nwith the Securities and Exchange Commission on May 13, 2026 (the “Original Report”). In the Original Report, the Company disclosed,\namong other events, the appointment of Ronald Silver, the Company’s Senior Vice President, Corporate Controller and Chief Accounting\nOfficer, as the Company’s interim chief financial officer and principal financial officer, effective May 15, 2026. This Amendment\nNo. 1 is being filed to provide a description of certain compensation arrangements approved by the Compensation and HR Committee (the\n“Committee”) of the board of directors of the Company on May 19, 2026 in connection with Mr. Silver’s new role as interim\nchief financial officer and principal financial officer. Except as set forth herein, this Amendment No. 1 does not amend, modify or update\nthe disclosure contained in the Original Report."}